{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:07:09Z","timestamp":1789711629579,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K08311"],"award-info":[{"award-number":["JP20K08311"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00262-023-03505-4","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T17:02:16Z","timestamp":1691427736000},"page":"3543-3558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions"],"prefix":"10.1007","volume":"72","author":[{"given":"Koki","family":"Uehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenro","family":"Tanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hozumi","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ariyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"3505_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"3505_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"3505_CR3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M et al (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer lmmunol Res 2:846\u2013856. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0040","journal-title":"Cancer lmmunol Res"},{"key":"3505_CR4","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1624","journal-title":"Clin Cancer Res"},{"key":"3505_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"3505_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G et al (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577:549\u2013555. https:\/\/doi.org\/10.1038\/s41586-019-1922-8","journal-title":"Nature"},{"key":"3505_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41416-020-0810-1","volume":"122","author":"H Ohmura","year":"2020","unstructured":"Ohmura H, Yamaguchi K, Hanamura F, Ito M, Makiyama A, Uchino K, Shimokawa H, Tamura S, Esaki T, Mitsugi K et al (2020) OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. Br J Cancer 122:1507\u20131517. https:\/\/doi.org\/10.1038\/s41416-020-0810-1","journal-title":"Br J Cancer"},{"key":"3505_CR8","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1111\/cas.13758","volume":"109","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Mishima K, Ohmura H, Hanamura F, Ito M, Nakano M, Tsuchihashi K, Ota SI, Wada N, Uchi H et al (2018) Activation of central\/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. Cancer Sci 109:3032\u20133042. https:\/\/doi.org\/10.1111\/cas.13758","journal-title":"Cancer Sci"},{"key":"3505_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R et al (2018) Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128:715\u2013720. https:\/\/doi.org\/10.1172\/JCI96798","journal-title":"J Clin Invest"},{"key":"3505_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline version 1.1. Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3505_CR11","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27, 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"key":"3505_CR12","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1210\/jc.2014-1049","volume":"99","author":"A Ricciuti","year":"2014","unstructured":"Ricciuti A, De Remigis A, Landek-Salgado MA, De Vincentiis L, Guaraldi F, Lupi I, Iwama S, Wand GS, Salvatori R, Caturegli P (2014) Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. J Clin Endocrinol Metab 99:1758\u20131766. https:\/\/doi.org\/10.1210\/jc.2014-1049","journal-title":"J Clin Endocrinol Metab"},{"key":"3505_CR13","doi-asserted-by":"publisher","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","volume":"9","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Iwama S, Sugiyama D, Yasuda Y, Okuji T, Ito M, Ito S, Sugiyama M, Onoue T, Takagi H et al (2021) Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors J Immunother. Cancer 9:e002493. https:\/\/doi.org\/10.1136\/jitc-2021-002493","journal-title":"Cancer"},{"key":"3505_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DY Heng","year":"2013","unstructured":"Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141\u2013148. https:\/\/doi.org\/10.1016\/S1470-2045(12)70559-4","journal-title":"Lancet Oncol"},{"key":"3505_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","volume":"20","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH et al (2022) Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:71\u201390. https:\/\/doi.org\/10.6004\/jnccn.2022.0001","journal-title":"J Natl Compr Canc Netw"},{"key":"3505_CR16","doi-asserted-by":"publisher","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","volume":"8","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T et al (2020) Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer 8:e000779. https:\/\/doi.org\/10.1136\/jitc-2020-000779","journal-title":"J Immunother Cancer"},{"issue":"22","key":"3505_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"15","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 15(22):886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"key":"3505_CR18","doi-asserted-by":"publisher","first-page":"701263","DOI":"10.3389\/fendo.2021.701263","volume":"12","author":"H Valeria","year":"2021","unstructured":"Valeria H, Ilaria B, Marianna M, Sada V, Sbardella E, Isidori AM (2021) Non-canonical effects of ACTH: insights into adrenal insufficiency. Front Endocrinol 12:701263. https:\/\/doi.org\/10.3389\/fendo.2021.701263","journal-title":"Front Endocrinol"},{"key":"3505_CR19","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3389\/fimmu.2019.02395","volume":"10","author":"P-Y Chen","year":"2019","unstructured":"Chen P-Y, Wu CY-J, Fang J-H, Chen HC, Feng LY, Huang CY, Wei KC, Fang JY, Lin CY (2019) Functional change of effector tumor-infiltrating CCR5 + CD38 + HLA-DR + CD8 + T cells in glioma microenvironment. Front Immunol 10:2395. https:\/\/doi.org\/10.3389\/fimmu.2019.02395","journal-title":"Front Immunol"},{"key":"3505_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00262-012-1360-z","volume":"62","author":"MJ McCoy","year":"2013","unstructured":"McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA (2013) Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother 62:529\u2013539. https:\/\/doi.org\/10.1007\/s00262-012-1360-z","journal-title":"Cancer Immunol Immunother"},{"key":"3505_CR21","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","volume":"14","author":"JH Finke","year":"2008","unstructured":"Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R et al (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14:6674\u20136682. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5212","journal-title":"Clin Cancer Res"},{"key":"3505_CR22","doi-asserted-by":"publisher","first-page":"577766","DOI":"10.3389\/fimmu.2021.577766","volume":"12","author":"D Ocadlikova","year":"2021","unstructured":"Ocadlikova D, Lecciso M, Broto JM, Scotlandi K, Cavo M, Curti A, Palmerini E et al (2021) Sunitinib exerts in vitro immunomodulatory activity on sarcomas via dendritic cells and synergizes with PD-1 blockade. Front Immunol 12:577766. https:\/\/doi.org\/10.3389\/fimmu.2021.577766","journal-title":"Front Immunol"},{"key":"3505_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","volume":"66","author":"B Huang","year":"2006","unstructured":"Huang B, Pan P-Y, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123\u20131131. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1299","journal-title":"Cancer Res"},{"key":"3505_CR24","doi-asserted-by":"publisher","first-page":"703918","DOI":"10.3389\/fimmu.2021.703918","volume":"12","author":"AJ Wishnie","year":"2021","unstructured":"Wishnie AJ, Chwat-Edelstein T, Attaway M, Vuong BQ (2021) BCR Affinity influences T-b interactions and B cell development in secondary lymphoid organs. Front Immunol 12:703918. https:\/\/doi.org\/10.3389\/fimmu.2021.703918","journal-title":"Front Immunol"},{"key":"3505_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty S (2014) T follicular helper cell differentiation, function, and roles in disease. Immunity 41:529\u2013542. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.004","journal-title":"Immunity"},{"key":"3505_CR26","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1136\/annrheumdis-2019-215195","volume":"78","author":"I Kurata","year":"2019","unstructured":"Kurata I, Matsumoto I, Ohyama A, Osada A, Ebe H, Kawaguchi H, Kaneko S, Kondo Y, Tsuboi H, Tomioka A et al (2019) Potential involvement of OX40 in the regulation of autoantibody sialylation in arthritis. Ann Rheum Dis 78:1488\u20131496. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215195","journal-title":"Ann Rheum Dis"},{"key":"3505_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clim.2013.02.024","volume":"147","author":"K Szabo","year":"2013","unstructured":"Szabo K, Papp G, Barath S, Gyimesi E, Szanto A, Zeher M (2013) Follicular helper T cells may play an important role in the severity of primary Sj\u00f6gren\u2019s syndrome. Clin Immunol 147:95\u2013104. https:\/\/doi.org\/10.1016\/j.clim.2013.02.024","journal-title":"Clin Immunol"},{"key":"3505_CR28","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.imbio.2016.04.005","volume":"221","author":"S Zhu","year":"2016","unstructured":"Zhu S, Lin J, Qiao G, Wang X, Xu Y (2016) Tim-3 identifies exhausted follicular helper T cells in breast cancer patients. Immunobiology 221:986\u2013993. https:\/\/doi.org\/10.1016\/j.imbio.2016.04.005","journal-title":"Immunobiology"},{"key":"3505_CR29","first-page":"2926","volume":"8","author":"ZQ Zhou","year":"2016","unstructured":"Zhou ZQ, Tong DN, Guan J, Tan HW, Zhao LD, Zhu Y, Yao J, Yang J, Zhang ZY et al (2016) Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages. Am J Transl Res 8:2926\u20132936","journal-title":"Am J Transl Res"},{"key":"3505_CR30","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","volume":"41","author":"PT Sage","year":"2014","unstructured":"Sage PT, Paterson AM, Lovitch SB, Sharpe AH (2014) The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 41:1026\u20131039. https:\/\/doi.org\/10.1016\/j.immuni.2014.12.005","journal-title":"Immunity"},{"key":"3505_CR31","doi-asserted-by":"publisher","first-page":"e002588","DOI":"10.1136\/jitc-2021-002588","volume":"9","author":"D Baumojohann","year":"2021","unstructured":"Baumojohann D, Brossart P (2021) T follicular helper cells: linking cancer immunotherapy and immune-related adverse events. J Immunother Cancer 9:e002588. https:\/\/doi.org\/10.1136\/jitc-2021-002588","journal-title":"J Immunother Cancer"},{"key":"3505_CR32","doi-asserted-by":"publisher","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6:230ra245. https:\/\/doi.org\/10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"key":"3505_CR33","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1073\/pnas.1908079116","volume":"116","author":"SA Tahir","year":"2019","unstructured":"Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J et al (2019) Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci USA 116:22246\u201322251. https:\/\/doi.org\/10.1073\/pnas.1908079116","journal-title":"Proc Natl Acad Sci USA"},{"key":"3505_CR34","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00262-021-03053-9","volume":"71","author":"M Seki","year":"2022","unstructured":"Seki M, Kitano S, Suzuki S (2022) Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. Cancer Immunol Immunother 71:769\u2013775. https:\/\/doi.org\/10.1007\/s00262-021-03053-9","journal-title":"Cancer Immunol Immunother"},{"key":"3505_CR35","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","volume":"82","author":"O Hasan Ali","year":"2020","unstructured":"Hasan Ali O, Bomze D, Ring SS, Berner F, F\u00e4ssler M, Diem S, Abdou MT, Hammers C, Emtenani S, Braun A et al (2020) BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 82:854\u2013861. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.045","journal-title":"J Am Acad Dermatol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03505-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03505-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03505-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:02:37Z","timestamp":1697266957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03505-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["3505"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03505-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KTa received honoraria from Ono Pharmaceutical. KY received honoraria from Ono Pharmaceutical and Chugai Pharmaceutical. HO received honoraria from Chugai Pharmaceutical. YM received honoraria from Kyowa Kirin. KTu received Ono Pharmaceutical and Taiho Pharmaceutical. ST received honoraria from Bayer, Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Merck, Daiichi-Sankyo, LSI Medience, and MSD. HS received honoraria from Ono Pharmaceutical, Eli Lilly, Merck. YS received honoraria from Eli Lilly, Daiichi-Sankyo and Kyowa Kirin. HK received honoraria from Chugai Pharmaceutical. HY received honoraria from AstraZeneca, Bayer, Chugai Pharmaceutical Novartis\u00a0Pharmaceutical. KA received honoraria from BMS, Ono Pharmaceutical, Janssen Pharmaceutical, Chugai Pharmaceutical, Kyowa Kirin, AbbVie GK, and Eisai; and research grants from Chugai Pharmaceutical, Kyowa Kirin, AbbVie GK, Asahi-Kasei, and Takeda Pharmaceutical. EB received honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, Merck, Sanofi, MSD, Eisai, and Daiichi-Sankyo; and research grants from Taiho Pharmaceutical, Chugai Pharmaceutical, and Eli Lilly. The other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethical Committee of Kyushu University Hospital (no. 29-348). Written informed consent was obtained from all patients prior to enrollment in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}